It wants to get ahead of competitors such as BMS, Merck, Pfizer, and in particular, its Swiss neighbours and cancer leaders Roche. The deal includes two recently approved GSK products for ...

which had forced it to lag behind competitors in the vaccine contracting season. By the time the mRNA-based vaccine was ...

GSK has stopped (PDF) development of one of the lead programs from its $2.1 billi | GSK has stopped development of one of the lead programs from its $2.1 billion Affinivax takeover, axing a phase 2 ...

The Zantac litigation had loomed heavily over GSK’s stock, contributing to underperformance compared to its competitors. Analysts at Jefferies noted that GSK’s stock is likely to “uptick ...

GSK is setting aside a mid-stage 24-valent pneumococcal vaccine program for adults to instead focus on a preclinical option that covers 30-plus valents, the company announced Wednesday alongside its ...

GSK CEO Emma Walmsley said the sector would need to wait to see who is appointed in key roles in the Trump administration to ...

Haleon was spun off from GSK amid investor pressure, showing steady growth but facing debt concerns. See more about HLN stock ...

GSK (GSK) stock was downgraded by Guggenheim Securities to neutral after the company's Q3 revenue decline. Read more here.

Competition is heating up in the RSV space, despite a lukewarm quarter for vaccine uptake. Pfizer beat GSK’s Arexvy for the first time in the third quarter, as Arexvy sales ...

GSK's severe asthma therapy Nucala could find ... which still has several years of patent life left before it could face biosimilar competition. The lung disease affects more than 300 million ...

Also Read: GSK’s Asthma Drug Meets Main Goal In Phase 3 Study In Patients With Smoker’s Lungs, Prepares Competition With Amgen/AstraZeneca’s Drug. The overall incidence and severity of ...